Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_4

67%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 42 (66.7%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

NCT02784613

completedphase_3

Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

NCT02638337

terminatedphase_4

Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

NCT03018106

Clinical Trials (3)

Showing 3 of 3 trials

NCT02784613Phase 4

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

Completed

NCT02638337Phase 3

Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

Completed

NCT03018106Phase 4

Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3